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Abstract: Glaucoma is a multifactorial optic neuropathy in which the main therapeutic target is 
lowering of intraocular pressure (IOP) in order to retard the progression of existing structural and 
functional damage. The three mainstays of treatment are pharmacologic, laser, and surgical. The 
primary standard therapy in patients with open-angle glaucoma or ocular hypertension is topical 
medication. When monotherapy does not adequately lower the intraocular pressure, one or more 
agents are added or substituted. Combination pharmacotherapy such as Cosopt® is available to 
improve efﬁ  cacy and simplify medication regimen. A ﬁ  xed combination of two ocular hypotensive 
drugs (the carbonic anhydrase inhibitor dorzolamide and the beta-adrenoceptor antagonist timolol), 
Cosopt® is indicated for the treatment of elevated IOP in patients with open-angle glaucoma or 
ocular hypertension insufﬁ  ciently responsive to topical beta-adrenoceptor antagonist monotherapy. 
Compared with concomitant therapy with the individual components, the primary advantage of 
ﬁ  xed combination dorzolamide – timolol is convenience, which may also improve compliance. 
Clinical trials have demonstrated that the ﬁ  xed combination dorzolamide – timolol is safe, 
effective and generally well tolerated in lowering IOP in patients with open angle glaucoma or 
ocular hypertension, including individuals uncontrolled on beta-adrenoceptor antagonist or other 
monotherapy.
Keywords: glaucoma, ocular hypertension, Cosopt®, ﬁ  xed combination dorzolamide – timolol, 
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Introduction
Glaucoma is a multifactorial optic neuropathy with elevated intraocular pressure (IOP) 
as a major risk factor. Increased IOP can eventually lead to characteristic glaucoma-
tous optic nerve damage and corresponding visual ﬁ  eld defects. This is one of the 
most common causes of blindness in the entire world, thus it is necessary that proper 
interventions be implemented at the earliest possible time to prevent further visual 
impairment (Martinez et al 1982). Lowering the IOP has been shown to signiﬁ  cantly 
reduce the risk of progression of glaucoma damage. Furthermore, the higher or lower 
the IOP at follow-up produced a respective increase or decrease in risk of progres-
sion (Leskea et al 2004). This holds true for both patients with ocular hypertension 
and those with normal tension glaucoma. Patients with ocular hypertension are those 
with IOP greater than 21 mmHg but do not exhibit optic nerve features suggestive of 
early glaucoma or do not have suspicious visual ﬁ  eld defects (Gordon et al 2002). The 
Normal Tension Glaucoma Study Group showed that a lowering of the IOP by 30%, 
regardless of method, had less progression of visual ﬁ  eld loss compared to those without 
treatments. This reduced IOP can be obtained and maintained by topical ophthalmic 
medications and/or laser trabeculoplasty (Schulzer et al 1992). Thus, the reduction 
of IOP to a level compatible with preservation of optic nerve function and stability Clinical Ophthalmology 2008:2(2) 390
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of visual ﬁ  elds remains the primary goal of all therapeutic 
modalities used in the treatment of glaucoma.
There are three mainstays to treatment of glaucoma: 
pharmacologic, laser, or surgical treatments. The ﬁ  rst line of 
therapy is topical medication. Many medications now exist 
to help control IOP in a variety of classes. Beta-adrenergic 
antagonists have been a mainstay of therapy for many years. 
They remain the most commonly prescribed drug, but more 
recent classes of glaucoma medications have come into favor. 
These include prostaglandin F2-alpha agonists, alpha-2 ago-
nists, and carbonic anhydrase inhibitors. The prostaglandin 
analogues have gained favor as primary therapy, but in many 
instances, beta-blockers remain the ﬁ  rst-line therapy in treat-
ment of glaucoma (Bateman et al 2002). Sometimes single 
agents do not achieve the desired therapeutic effects, thus 
combinations of medications from various classes can be used 
to attempt to achieve the desired results. When more medi-
cations are added, however, the treatment regimen becomes 
more complicated and patient compliance becomes a concern 
(Kaiserman et al 2005). It is for this reason that combination 
pharmacotherapy has come into favor in glaucoma treatment 
(Martone and Mead 2001).
If pharmacotherapy continues to provide insufﬁ  cient low-
ering of IOP, surgical options exist. Glaucoma surgery can 
be accomplished with laser or incisional surgical techniques 
(Bateman 2002). The 5-year results of the Collaborative Ini-
tial Glaucoma Treatment Study (CIGTS) showed that both 
initial surgical or medical therapy resulted in similar visual 
ﬁ  eld outcome. While there was a noted decreased visual 
acuity initially in the surgery treated group, this difference 
seemed to resolve as the length of follow-up progressed 
(Lichter et al 2001). Thus, patients with glaucoma are treated 
either medically or surgically to lower the intraocular pres-
sure in order to prevent further progression of the glaucoma 
disease process.
Pharmacology, mode of action, 
pharmacokinetics
One combination topical medication commercially available 
is Cosopt® (Merck and Co., Inc., Whitehouse Station, NJ, 
USA), which consists of dorzolamide hydrochloride 2% 
(CAS Registry # 130693) and timolol maleate 0.5% (CAS 
Registry # 26921-17-5). Each mL of Cosopt® contains 20 mg 
dorzolamide (22.26 mg dorzolamide hydrochloride) and 
5 mg timolol (6.83 mg timolol maleate), as well as sodium 
citrate, hydroxyethyl cellulose, sodium hydroxide, mannitol, 
water, and 0.0075% benzalkonium chloride as a preserva-
tive (Cosopt® online 2007). The formulation is available in 
5 or 10 mL quantities containing 175 and 321 drops/bottle, 
respectively. Dorzolamide hydrochloride is a topical carbonic 
anhydrase II inhibitor and timolol maleate is a topical beta-
adrenergic receptor blocking agent. In combination, they are 
approved to reduce elevated IOP in patients with open-angle 
glaucoma or ocular hypertension and with insufﬁ  cient IOP 
response to beta-blockers monotherapy (Cosopt® online 
2007).
Both dorzolamide and timolol help reduce IOP by 
decreasing the production of aqueous humor by the cili-
ary body. Carbonic anhydrase inhibition slows the forma-
tion of bicarbonate ions thereby decreasing the amount of 
sodium and ﬂ  uid transport. With such a decrease in ﬂ  uid 
transport comes a decreased production of aqueous humor. 
Dorzolamide decreases the secretion of aqueous humor in 
the ciliary processes by inhibition of carbonic anhydrase II, 
the most active isoenzyme and found primarily in red blood 
cells. Thus, chronic administration of dorzolamide causes an 
accumulation of the medication within red blood cells. This 
drug also binds moderately to plasma proteins. Metabolism 
of dorzolamide produces N-desthyl which also binds to red 
blood cells to inhibit carbonic anhydrase I to a greater extent 
than carbonic anhydrase II. The major route of excretion is 
through the urine for both the parent and metabolite drug. 
Upon discontinuation of the medication there is a rapid initial 
decline of the medicine from the red blood cells followed by 
a much slower decline due to an elimination-phase half-life 
of approximately 4 months. Carbonic anhydrase inhibitor has 
been reported to increase ocular blood ﬂ  ow parameters by 
causing ocular vasodilation through metabolic acidosis via 
elevated carbon dioxide levels in the eye tissues in normal ten-
sion glaucoma patients (Sugrue 2000). A high concentration 
of topically applied dorzolamide has been shown to reach the 
choroid of the posterior pole of the eye (Sugrue et al 1990). 
It has been a popular adjunctive agent and is often used as 
monotherapy. Dorzolamide is also a safer alternative to the 
oral carbonic anhydrase inhibitor, acetazolamide and meth-
azolamide, in the treatment of primary open-angle glaucoma 
or ocular hypertension. Dorzolamide reduces IOP from base-
line at trough by 15%–19% and at peak by 20%–24%.
Timolol is a non-selective beta-adrenergic antagonist. 
Reducing aqueous humor ﬂ  ow is the main mechanism by 
which beta blockers like timolol have been shown to lower 
IOP. Timolol presumably exerts a direct action on the beta-2 
adrenergic receptors in the ciliary processes to decrease aque-
ous humor secretion and possibly on local capillary perfusion 
to reduce ultraﬁ  ltration (Hoyng and Van Beek 2000; Neufeld 
et al 1983). Reduction of aqueous humor production may be Clinical Ophthalmology 2008:2(2) 391
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secondary to inhibition of catecholamine-stimulated synthesis 
of cyclic adenosine monophosphate (AMP) in ciliary epithe-
lium, which has been demonstrated in rabbit studies (Bartels 
et al 1980; Nathanson 1980). However, the regulation of aque-
ous humor dynamics is complex and still not fully understood. 
Studies have shown a topical timolol effect on aqueous ﬂ  ow 
in the fellow, untreated eye in patients with open-angle glau-
coma and with ocular hypertension (Piltz et al 2000). Timolol 
decreases IOP by approximately 20%–30%.
Fuchsjager-Mayrl et al published a study comparing 
the effect of ocular ﬂ  ow by dorzolamide and timolol in 140 
patients with POAG or ocular hypertension. At the end of 
the 6 months, the authors found comparable effects of both 
drugs on IOP and ocular perfusion pressure but statistically 
signiﬁ  cant increased blood ﬂ  ow in the optic nerve head and 
choroid with dorzolamide but not with timolol (Fuchsjager-
Mayrl et al 2005). In a study comparing Cosopt® with timolol, 
Cosopt® was found to increase the arteriovenous passage time 
through the superior retinal vasculature seen on ﬂ  uorescein 
angiography (Harris et al 2001).
Safety and efﬁ  cacy studies
The safety and efﬁ  cacy of the ﬁ  xed combination dorzolamide – 
timolol (FCDT) have been evaluated in several large phase 
III randomized controlled studies in patients with open angle 
glaucoma or ocular hypertension. The safety proﬁ  le of the 
combination was essentially equivalent to concomitant 
administration of its components. The results also showed 
that the FCDT is as effective as its components used 
concomitantly in controlling IOP and demonstrated greater 
IOP lowering effect than either of its components used as 
monotherapy. Several independent studies have conﬁ  rmed 
the safety and efﬁ  cacy ﬁ  ndings. The following are a sum-
mary highlighting some of the studies comparing the safety 
and efﬁ  cacy of FCDT alone, FCDT with its components, and 
FCDT with other IOP-lowering topical medications.
FCDT as monotherapy
Henderer et al studied the IOP-lowering effect of FCDT as 
initial treatment in 18 patients with IOP over 30 mmHg in 
a 2-month prospective interventional case series. Over 80% 
of the eyes responded to FCDT, with an average trough IOP 
reduction of 40%. Mean peak IOP reduced from 37.5 mmHg 
to 18.4 mmHg (p  0.01) (Henderer et al 2005).
FCDT vs monotherapy with dorzolamide 
or timolol (Table 1)
The Dorzolamide-Timolol Study Group compared the safety 
and efﬁ  cacy of FCDT to monotherapy with either timolol 
0.5% twice daily or dorzolamide 2% three times daily in 335 
patients after a washout of their hypotensive monotherapy 
agents. They found from the Phase 3 trials that FCDT pro-
vided superior IOP-lowering efﬁ  cacy compared to either dor-
zolamide or timolol alone. The incidence of clinical adverse 
events was comparable in all three groups: 57 in FCDT group, 
63 in dorzolamide group, and 53 in timolol group. More 
patients in the FCDT group than the timolol group reported 
ocular burning, stinging, tearing, taste perversion and blurry 
vision; the numbers were comparable between the FCDT and 
dorzolamide groups (Boyle et al 1998).
In 253 patients whose IOP was inadequately controlled on 
timolol montherapy, the Dorzolamide-Timolol Combination 
Table 1 FCDT vs dorzolamide or timolol
Authors Time point Treatment N Baseline Treatment Changea % Change
IOPa IOPa
Boyle et al Mos 3 Trough FCDT 114 27.8(5.0) 20.1(4.5) −7.7(4.2) −27.4(13.1)
Dorzolamide 109 28.1(4.7) 23.5(4.2) −4.6(4.3) −15.5(13.5)
Timolol 111 27.9(4.6) 21.5(4.0) −6.4(4.1) −22.2(12.5)
Mos 3 Peak FCDT 112 27.1(4.3) 18.1(3.8) −9.0(4.3) −32.7(12.9)
Dorzolamide 109 27.3(3.8) 21.8(4.3) −5.4(3.6) −19.8(12.6)
Timolol 110 27.3(4.4) 21.0(4.7) −6.3(4.7) −22.6(15.6)
Clineschmidt et al Mos 3 Trough FCDT 102 25.5(3.4) 22.7(3.9) −2.8(3.4) −10.6(12.5)
Dorzolamide 51 25.5(3.8) 24.2(5.1) −1.4(4.3) −4.9(16.7)
Timolol 98 25.2(3.1) 23.6(4.3) −1.7(3.1) −6.7(11.9)
Mos 3 Peak FCDT 103 25.0(3.9) 20.7(4.5) −4.4(3.3) −17.3(12.9)
Dorzolamide 51 24.7(3.3) 22.7(3.8) −2.0(4.1) −7.4(15.8)
Timolol 95 24.3(2.6) 22.8(4.6) −1.6(3.7) −6.6(15.3)
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 392
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Study Group also found that the FCDT was superior to either 
of the components given individually in lowering the IOP 
and is as well-tolerated as the dorzolamide component. At 
the end of the 3 month study, the FCDT group achieved 
greater percentage of IOP reduction at both morning trough 
and peak. The safety proﬁ  le of the FCDT reﬂ  ected that of its 
individual components. The percentage of patients reporting 
ocular or local adverse events was equal in the FCDT (45%) 
and dorzolamide (45%) groups and greater than the timolol 
(27%) group (Clineschmidt et al 1998).
FCDT vs concomitant dorzolamide 
and timolol (Table 2)
Francis et al (2004), Hutzelmann et al (1998), and Strohmaier 
et al (1998) conducted randomized trials comparing the IOP 
lowering effect of concomitant use of timolol 0.5% and 
dorzolamide 2% to that of the FCDT. The results of their 
studies indicate that the ﬁ  xed combination was as at least as 
effective as its components given concomitantly in control-
ling IOP (no statistically signiﬁ  cant difference). However, 
in the replacement study designed to mimic the “real world” 
uncontrolled clinical practice setting, there was a highly 
signiﬁ  cant (p  0.0001) IOP effect when switching from the 
concomitant use of the individual components to the FCDT, 
as 81.1% patients had an IOP equal to or less than the starting 
IOP. FCDT decreased IOP by a mean of 1.7 mmHg (8.8%) 
from baseline of 19.4 mmHg (Francis et al 2004). When 
comparing the incidence of drug-related adverse experiences 
and resultant discontinuations, Hutzelmann et al did not ﬁ  nd 
a statistically signiﬁ  cant difference between the FCDT group 
and the concomitant group (Hutzelmann et al 1998). Both the 
FCDT and concomitant groups lowered IOP from timolol 
baseline by the same percentage at trough and peak in 290 
patients who completed the study (Hutzelmann et al 1998). 
At the end of the 3-month, multicenter, parallel, randomized, 
double-masked trial of 242 patients, Strohmaier et al found 
that FCDT lowered IOP 14%–20% compared to 16%–20% in 
the concomitant group, with greater than 97% conﬁ  dence that 
the treatments were equivalent (Strohmaier et al 1998).
FCDT vs concomitant brimonidine and 
timolol (Table 3)
Sall et al compared the efﬁ  cacy and tolerability of the FCDT 
twice daily to the concomitant administration of 0.2% bri-
monidine twice daily and 0.5% timolol twice daily. In this 
6-month, randomized, multicenter, observer-masked, paral-
lel-group study, 293 patients with ocular hypertension or 
primary open-angle glaucoma participated. The efﬁ  cacy of the 
FCDT and the concomitant administration of brimonidine and 
timolol were comparable. Both groups had similar incidence 
of drug-related adverse experiences and resultant discontinu-
ations. Ninety-three patients (64%) in the FCDT group and 
88 patients (60%) in the concomitant group reported adverse 
events which the investigator attributed to the drugs; 7 patients 
(5%) in the FCDT group and 8 patients (5%) in the concomi-
tant group discontinued the study (Sall et al 2003).
In a randomized, observer-masked, multicenter study of 
492 patients with ocular hypertension, primary open-angle 
Table 2 FCDT vs dorzolamide + timolol (D + T)
Authors Time point Treatment N Baseline 
IOPa
Treatment 
IOPa
Changea % Change
Francis et al Mos 1 FCDT 74 21.0(4.3) 19.5(4.6) −1.5 −7.1
Trough D + T 57 19.8(3.5) 19.0(3.3) −0.8 −4.0
FCDT 74 18.4(3.6) 17.6(3.6) −0.8 −4.3
Mos 1 Peak D + T 57 17.6(3.8) 17.3(3.5) −0.3 −1.7
Hutzelmann et al Mos 3 FCDT 151 25.6(3.1) 21.4(4.1) −4.2(3.3) −16.3(12.5)
Trough D + T 148 25.3(3.2) 21.1(3.7) −4.2(3.1) −16.3(11.5)
FCDT 151 24.7(3.2) 19.4(3.7) −5.4(3.1) −21.6(12.3)
Mos 3 Peak D + T 148 24.5(3.2) 19.1(3.5) −5.4(3.3) −21.8(11.9)
Strohmaier et al Mos 3 FCDT 120 26.1(3.0) 22.5(4.1) −3.6(3.0) −13.8(11.1)
Trough D + T 121 26.1(3.8) 22.0(4.4) −4.1(3.7) −15.5(13.8)
FCDT 119 25.1(3.3) 20.1(3.8) −5.0(3.5) −19.7(12.9)
Mos 3 Peak D + T 120 25.0(3.7) 20.2(4.2) −4.9(3.8) −19.1(14.4)
FCDT 116 23.7(3.9) 20.0(3.9) −3.7(3.4) −14.9(13.2)
Mos 3 Hr. 8 D + T 118 23.3(4.2) 19.0(3.5) −4.3(3.8) −17.4(14.8)
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 393
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glaucoma, exfoliative glaucoma, or pigmentary glaucoma, 
Solish et al reported comparable IOP-lowering effects between 
FCDT and concomitant brimonidine and timolol treatment at 
3 of the 4 timepoints measured at month 1 and 3 of treatment 
following a 3-week timolol run-in period. The only statisti-
cally signiﬁ  cant treatment difference occurred at month 3 peak 
measurement, when the concomitant group had a 0.97 mmHg 
additional IOP-lowering advantage over the FCDT group. The 
incidence of drug-related adverse experiences was similar 
between treatment groups. Patient-reported assessments of 
convenience and satisfaction showed no statistically signiﬁ  cant 
differences between treatment groups (Solish et al 2004).
FCDT vs prostaglandin analogs (latanoprost, 
bimatoprost) (Tables 4 and 4-1)
The European Latanoprost Study Group randomized 226 
patients whose IOP was insufﬁ  ciently controlled by timolol 
alone to receive either latanoprost once daily or the FCDT 
twice daily. Intraocular pressure was measured at 10:00 am 
and 5:00 pm at baseline and after 3 months of treatment. They 
found that IOP reduction by monotherapy with latanoprost 
was comparable to that achieved by the FCDT, with a mean 
reduction of 19% for the latanoprost treatment group and 17% 
for the FCDT group (p  0.05) (Honrubia 2002). Likewise, 
Orzalesi et al found that both FCDT and latanoprost resulted 
in similar circadian reductions in IOP without statistically 
signiﬁ  cant differences between the mean diurnal IOP values 
between the two groups (Orzalesi et al 2003). Fechtner et al 
compared the efﬁ  cacy of FCDT with latanoprost in two 
3-month, parallel group, randomized, double-masked, mul-
ticenter, clinical studies in patients with ocular hypertension 
or open-angle glaucoma. Study 1 (n = 256) was conducted 
in the United States and Study 2 (n = 288) was conducted in 
Europe/Israel. They found that FCDT and latanoprost were 
equally effective at lowering IOP. Both treatments reduced 
IOP by about 25%–30%. Both treatments were well tolerated, 
Table 3 FCDT vs brimonidine + timolol (B + T)
Authors Time point Treatment N Baseline 
IOPa
Treatment 
IOPa
Change in 
IOPa
Treatment 
difference*
p-value
Solish et al Mos 1 FCDT 231 24.78(3.39) 21.11(3.94) 3.57(0.24)
Trough B + T 238 24.53(3.14) 20.83(4.24) −3.66(0.24) 0.09(0.29) 0.767
FCDT 224 24.01(2.78) 19.03(3.51) −4.93(0.24)
Mos 1 Peak B + T 231 24.07(2.68) 18.59(4.08) −5.40(0.23) 0.47(0.29) 0.102
Mos 3 FCDT 235 24.82(3.41) 21.23(4.39) −3.31(0.26)
Trough B + T 243 25.50(3.12) 20.79(3.92) −3.52(0.25) 0.21(0.31) 0.491
FCDT 228 24.05(2.83) 19.60(3.95) −4.30(0.24)
Mos 3 Peak B + T 237 24.03(2.68) 18.58(3.95) −5.27(0.23) 0.97(0.29) 0.001
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.
Table 4 FCDT vs latanoprost
Authors Time point Treatment Mean baseline
IOPa
Mean treatment
IOPa
p-value
Orzalesi et al Mos 1 FCDT 22.6(2.7) 16.9(1.4)
Latanoprost 22.6(2.7) 16.7(0.6) 0.05
Fechtner et al Mos 3(Study 1) FCDT 26.1 18.9
Latanoprost 25.6 18.4 0.05
Mos 3(Study 2) FCDT 25.3 17.4
Latanoprost 24.7 17.5 0.05
Konstas et al (2003b) Week 6 FCDT 25.8(1.4) 15.3(2.0)
Latanoprost 25.8(1.4) 15.9(2.3) 0.05
Konstas et al 
(pseudoexfoliation
patients) (2003a)
Mos 2 FCDT
Latanoprost
31.2(6.5)
31.2(6.5)
18.1(3.0)
18.9(4.1) 0.21
Susanna et al Mos 2 FCDT 23.6(3.3) 17.2(3.1)
Latanoprost 23.5(2.8) 16.6(3.0) 0.05
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 394
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although ocular stinging occurred more frequently with the 
FCDT (Fechtner et al 2004).
In a randomized, open-label and cross-over study, Janu-
leviciene et al compared the effects of FCDT and latanoprost 
on IOP and pulsatile ocular blood ﬂ  ow in 30 POAG patients. 
Their study found that both FCDT and latanoprost signiﬁ  cantly 
reduced IOP, with FCDT exerting signiﬁ  cantly greater IOP 
lowering effect than latanoprost (p  0.05). Both groups also 
signiﬁ  cantly increased pulsatile ocular blood ﬂ  ow by 2.048 
μL/second (p = 0.003) and 2.147 μL /second (p = 0.0009), 
respectively. However, FCDT signiﬁ  cantly increased pulse 
volume by 0.767 μL (p = 0.0087), whereas latanoprost did 
not have a signiﬁ  cant effect (p = 0.2407) (Januleviciene et al 
2004). Similarly, Konstas et al concluded from their study 
that FCDT has a small numerical (0.6 mmHg) but statistical 
advantage (p = 0.05) over latanoprost in lowering the 24-hour 
diurnal IOP in patients with POAG and ocular hypertension. 
The FCDT lowered IOP by about 41% and and the latanoprost 
by about 38% (Konstas et al 2003b).
However, in another study evaluating 65 patients with 
newly diagnosed exfoliation glaucoma, Konstas et al found 
statistically insignificant treatment difference between 
latanoprost and the FCDT. The FCDT showed a signiﬁ  cantly 
greater incidence of taste perversion (p  0.001) and sting-
ing upon instillation (p = 0.036), while latanoprost showed 
a trend for increased conjunctival injection (p = 0.056). In 
addition, ﬁ  ve patients demonstrated either bradycardia or 
asthmatic symptoms with initiation of the FCDT therapy. 
One patient on latanoprost complained of dizziness. Patients 
preferred latanoprost (63 vs 20.3%) mainly because of its 
once daily dosing (p  0.001) (Konstas et al 2003a).
Susanna et al reported results from an interventional, 8-
week, randomized, open-label, parallel-group study conducted 
at 18 centers in 6 Latin American countries. The efﬁ  cacy and 
tolerability of latanoprost with that of the FCDT were evaluated 
in 229 patients with unilateral or bilateral primary open-angle, 
pigmentary, or exfoliative glaucoma or ocular hypertension. 
Mean IOP reductions were generally similar between treatment 
groups, except at 5:00 pm, when the mean IOP level was signiﬁ  -
cantly lower in latanoprost-treated patients (p = 0.025). From a 
similar mean baseline IOP, the latanoprost group reduced IOP 
by 29.3% while the FCDT group reduced 26.5%. After the 
water-drinking test, which estimates the peak IOP of diurnal 
tension curve, the increase in IOP values was similar between 
groups at baseline but lower in latanoprost-treated patients at 
week 8 (adjusted difference, 1.08 mmHg; p = 0.012). Latano-
prost was better tolerated than FCDT. Fewer patients treated 
with latanoprost reported ocular or systemic adverse events (p 
= 0.025 and p  0.001, respectively) (Susanna et al 2004).
In a double-masked, prospective, three-center, random-
ized, crossover study of 35 patients by Day et al the efﬁ  cacy 
and safety of bimatoprost given every evening was compared 
to FCDT given twice daily for 2 months in open-angle glau-
coma and ocular hypertensive patients. The study showed 
that both groups similarly reduced the intraocular pressures 
from baseline for each time point and for the diurnal curve 
(p  0.05). In terms of ocular safety and tolerability, there 
was more conjunctival hyperemia with bimatoprost (n = 15) 
than with FCDT (n = 7, p = 0.013) and more burning and 
stinging with FCDT (n = 12) than with bimatoprost (n = 0, 
p = 0.0005). Few systemic adverse events were recorded and 
there was no statistical difference between groups for any 
individual event (p  0.05) (Day et al 2005).
In a Turkish study, Ozturk et al also reported statistically 
insigniﬁ  cant differences in IOP reduction between the bimato-
prost (6.2 mmHg) and FCDT (6.5 mmHg) groups at all study 
visits (p  0.05) in 65 patients with POAG or ocular hyper-
tension during 6 months of treatment. Both bimatoprost and 
FCDT were generally well tolerated. All but two cases of ocular 
adverse experiences were mild and transient in both groups. 
The incidence of reported ocular and systemic adverse events 
were statistically insigniﬁ  cant between the two groups except 
Table 4-1 FCDT vs bimatoprost
Authors Time point Treatment Mean baseline
IOPa
Mean treatment 
IOPa
Treatment 
difference*
p-value
Day et al (2005) Mos 2 FCDT 24.8(2.4) 18.1(2.8)
Bimatoprost 24.8(2.4) 17.4(2.9) 0.7 0.35
Ozturk et al Mos 6 FCDT 24.1(2.1) 17.6(2.9)
Bimatoprost 23.7(2.0) 17.5(2.3) 0.3 0.48
Coleman et al Mos 3 (8 AM) FCDT 24.8(2.5) 19.8
Bimatoprost 25.0(2.5) 18.2 1.8 0.001
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 395
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for conjunctival hyperemia (n = 18 in the bimatoprost group vs 
4 in the FCDT group, p = 0.02) (Ozturk et al 2007).
For patients whose IOP does not respond to latanoprost, 
adding or switching to FCDT has also been found to be 
beneﬁ  cial. In a Spanish retrospective review of records from 
31 patients (including 18 with pseudoexfoliative glaucoma), 
Martinez and Sanchez evaluated the intraocular pressure 
lowering effect of FCDT in patients with inadequate response 
to prostaglandin analogs/prostamides (less than 15% IOP 
lowering from baseline). FCDT signiﬁ  cantly reduced IOP in 
the patients overall, from 25.4 to 20.2 mmHg (p  0.0001). 
FCDT reduced the mean IOP ﬂ  uctuations over 12 hours 
(highest minus lowest IOP reading within the 12-hours pres-
sure curve) from 8.6 to 4.3 mmHg (p  0.0001). The most 
common adverse events were ocular burning (16%) and taste 
perversion (13%). There were no serious treatment-related 
adverse events (Martinez and Sanchez 2007).
It is worth noting that a few studies have shown pros-
taglandin analogs as being more efﬁ  cacious than FCDT in 
reducing IOP. In a study by Caca et al 39 POAG patients 
who had been using FCDT for at least three months were 
switched to latanoprost monotherapy. At the end of 3 months, 
the study showed a statistically signiﬁ  cant reduction of mean 
IOP from 13.6 to 12.2 mmHg (p = 0.01). Latanoprost elicted 
more hypermia (p  0.0001) while FCDT caused more burn-
ing on instillation (p  0.0001) (Caca et al 2006). Similarly, 
Coleman et al found that bimatoprost lowered IOP more 
consistently and signiﬁ  cantly than FCDT in a 3-month ran-
domized controlled trial on patients with glaucoma or ocular 
hypertension and uncontrolled IOPs on topical beta-blocker 
alone. Patients had better diurnal IOP control with bimatoprost 
than FCDT. Taste perversion, ocular burning, and stinging 
with instillation were more common with FCDT, whereas 
conjunctival hyperemia was more common with bimatoprost 
(Coleman et al 2003).
FCDT vs concomitant timolol 
and unoprostone (Table 5)
In another prospective multicenter, randomized, double-
masked, crossover comparison study, Day et al found similar 
efﬁ  cacy and safety between FCDT and concomitant use of 
timolol maleate 0.5% and unoprostone 0.15% in 32 patients 
with primary open-angle glaucoma or ocular hypertension. 
After a 4-week run-in period on timolol 0.5% twice daily, the 
patients received one treatment for 6 weeks and then crossed 
over to the opposite treatment. The authors found comparable 
IOP reduction for all the time points, for the diurnal curve, 
or in the extended reduction from baseline. There was no 
difference between treatment groups regarding ocular and 
systemic unsolicited or solicited adverse events. Burning, 
stinging, and conjunctival hyperemia were the adverse events 
most noted (Day et al 2003).
FCDT vs ﬁ  xed combination 
brimonidine–timolol (FCBT) (Table 6)
In a prospective, multicenter, observer-masked, crossover 
study of 30 patients with POAG or ocular hypertension, 
Arcieri et al reported similar IOP-lowering efﬁ  cacy by both 
FCDT and FCBT, with signiﬁ  cant reduction of baseline IOP 
(p  0.00001). Following 4 weeks of therapy, the mean diur-
nal IOP reduction was 7.8 mmHg for FCBT and 7.4 mmHg 
for FCDT (p = 0.430). Overall, 14 subjects complained about 
ocular adverse events (ocular stinging/burning, conjunctival 
hyperemia, itching, tearing, discharge, and dry eyes): 2 only 
for FCBT, 7 only for FCDT, and 5 for both drugs. Although 
there was no signiﬁ  cant difference between the number of 
subjects that reported ocular adverse events with FCBT 
(n = 7) and FCDT (n = 12) (p = 0.359), FCDT caused more 
ocular stinging upon instillation (n = 9) than FCBT (n = 1) 
(p = 0.027). No one discontinued the study due to the adverse 
experiences (Arcieri et al 2007).
FCDT vs ﬁ  xed combination 
pilocarpine–timolol (FCPT) (Table 7)
Kaluzny et al compared the efﬁ  cacy and safety of FCDT 
with FCPT, each given twice daily, in patients with POAG 
or ocular hypertensive patients. Their 6-week study found 
that both FCDT and FCPT resulted in similar efﬁ  cacious 
IOP reduction. There were statistically more unsolicited 
reports of vision change and ocular pain associated with 
Table 5 FCDT vs timolol + unoprostone (T + U)
Authors Time point Mean baseline IOPa IOP in FCDT a IOP in T + Ua p-value
Day et al (2003) Week 6 Trough 
Diurnal curve
24.3(3.0) 20.8(4.1) 20.1(4.5) 0.55
23.4(3.2) 19.6(3.6) 19.8(4.1) 0.63
a measured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 396
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FCPT (p = 0.04). Six patients were discontinued early from 
FCPT therapy (17%) versus two from FCDT (6%) (p = 0.13) 
(Kaluzny et al 2003).
FCDT vs ﬁ  xed combination 
latanoprost–timolol (FCLT) (Table 8)
In another study published by Konstas et al the diurnal 
efﬁ  cacy and safety were compared between the FCLT given 
once daily and the FCDT given twice daily in POAG or 
ocular hypertensive patients. In this double-masked, two-
center, crossover comparison of 33 patients, the daytime 
diurnal IOP was not statistically different between FCLT 
and FCDT. Additionally, they did not ﬁ  nd statistical dif-
ference for individual time points. A bitter taste was found 
more frequently with FCDT (n = 6) than FCLT (n = 0) 
(p = 0.040), while FCLT demonstrated more conjunctival 
hyperemia (n = 9) than FCDT (n = 2) (p = 0.045) (Konstas 
et al 2004).
In contrast, another study comparing FCLT and FCDT 
found a statistically signiﬁ  cant difference in IOP-lowering 
efﬁ  cacy. Shin et al enrolled 253 patients with POAG or 
ocular hypertension inadequately responsive to monotherapy 
in a 3-month, randomized, parallel group, observer-masked, 
multicenter study. The FCLT was found to be slightly 
more effective than FCDT in reducing mean diurnal IOP 
(9.4 mmHg vs 8.4 mmHg, p = 0.005). Both treatments 
generally were well tolerated. Transient eye pain during 
instillation of the medications was the only reported adverse 
event with signiﬁ  cant difference between the two groups 
(11.7% in FCDT vs. 4.0% in FCLT, p = 0.034) (Shin et al 
2004).
FCDT vs concomitant brimonidine 
and latanoprost (Table 9)
Zabriskie and Netland performed two double-masked, 
randomized, parallel, multicenter trials of similar design 
comparing the IOP-lowering efficacy of concomitant 
brimonidine 0.2% and latanoprost 0.005% with the FCDT in 
patients with glaucoma or ocular hypertension. The results 
showed that the combination of brimonidine and latanoprost 
produced greater mean IOP reductions at each visit in both 
trials (Zabriskie and Netland 2003).
Patient-focused perspectives
In addition to a medication’s pharmacological potency, 
patient compliance also plays a major role in medica-
tion efﬁ  cacy. Poor compliance leads to therapy failure. A 
well-known study by Kass et al showed the difﬁ  culties of 
compliance in a glaucoma population. Non-compliance was 
detected in 28%–59% of the patients instilling pilocarpine 
four times daily with a bottle embedded with a microchip 
sensor unbeknownst to the patients. However, 97% of the 
patients reported good compliance. The treating physicians 
could not predict which patients had poor or good compli-
ance (Kass et al 1986).
Compliance is inﬂ  uenced also in part by regimen com-
plexity. Most of the patients with glaucoma are over age 
65, have concurrent medical problems and may be taking 
multiple chronic medications. Greenburg found that the rate 
of compliance drops from 70% to approximately 50% when 
more than two medications (including ophthalmic) are used 
(Greenburg 1984). Other studies have also found an associa-
tion between regimen complexity and decreased compliance 
Table 6 FCDT vs FCBT
Authors Time point Treatment Mean baseline 
IOPa
Mean treatment
IOPa
Treatment 
differencea
p-value
Arcieri et al Mos 1 FCDT 22.9(1.6) 15.4(2.1)
FCBT 22.9(1.6) 15.0(2.1) 0.4 0.43
a measured in mmHg.
SD values provided in parenthes.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; FCBT, ﬁ  xed combination brimonidine–timolol; IOP, intraocular pressure; mos, months.
Table 7 FCDT vs FCPT
Authors Time point Mean baseline
IOPa
IOP in FCDT a IOP in FCPT a p-value
Kaluzny et al Week 6 Trough 
Diurnal curve
23.4(2.3) 18.0(2.2) 17.4(2.0) 0.22
22.3(3.7) 18.1(2.2) 16.7(1.9) 0.0007
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; FCPT, ﬁ  xed combination pilocarpine–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 397
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(Patel and Spaeth 1995; Weinreb 1992). Compliance with 
medical therapy drops greatly when using a medication 
three times a day versus twice a day (Morgan et al 1986). 
Therefore, simplifying the treatment regimen may enhance 
compliance. This involves critically evaluating whether 
multiple medications are necessary, especially when adding 
medications. Combination medications such as ﬁ  xed combi-
nation dorzolamide – timolol have considerable clinical value 
for the glaucoma patient population by simplifying treatment 
regimen. The improved convenience of instilling fewer daily 
drops with one bottle of the combination formulation and 
the elimination of potential confusion of frequency between 
two bottles of solution may enhance patient compliance. In a 
Swiss survey by Gugleta, increased compliance and subjec-
tive convenience were suggested reasons for the average IOP 
decrease of 1.5 mmHg upon switch from dorzolamide and 
timolol to the combination therapy and high continuation rate 
on the combination therapy (Gugleta et al 2003). However, 
of the ﬁ  xed-combination glaucoma medications, Cosopt® 
and Combigan® are used twice daily, while Xalacom® only 
requires a once daily regimen that may thereby increase 
compliance. Of these three medications Cosopt® provides 
the largest drop volume, and therefore the smallest number 
of drops per mL. In Canada, this may partially account for 
the slightly higher cost of Cosopt® compared to the other two 
medications, with Cosopt® costing $1.22 per day compared to 
$1.09 and $0.87 for Xalacom® and Combigan®, respectively. 
This creates an annual cost difference between Cosopt® 
and Combigan® of approximately $130. The greater cost 
of Cosopt® compared to the other ﬁ  xed-combinations may 
hamper the patients’ ability to afford the medication, so this 
is a real concern that must be investigated by the physician 
when deciding a treatment modality. The efﬁ  cacy of these 
medications should be compared to determine if the greater 
cost of Cosopt® is offset by a greater efﬁ  cacy in glaucoma 
treatment (Ventura et al 2005).
In addition to convenience and cost, tolerability is also a 
major component in patient compliance. Additional concerns 
may exist with the potential side effects of the individual 
components of this medication. Timolol maleate, as a beta-
blocking agent, may have signiﬁ  cant cardiopulmonary effects 
in patients as beta-1 and beta-2 receptors are found in the 
heart and lung, respectively. Those patients with known 
cardiac or previous chronic obstructive pulmonary disease 
(COPD) diagnoses should be cautioned against using this 
class of drug altogether. Dorzolamide is of the class sulfon-
amide which could lead to an allegic reaction in patients with 
known allergies to this class of medication. Thus, caution 
should be employed with all patients when subscribing this 
ﬁ  xed combination of medicines (Ormrod and McClellan 
2000). Although the ﬁ  xed combination dorzolamide – timolol is 
generally well tolerated, it is associated with ocular discom-
fort on installation and led to discontinuation by a minority 
of patients in a number of studies. Approximately 5% of 
the 1035 patients in Phase III clinical trials discontinued 
therapy with ﬁ  xed combination dorzolamide – timolol due 
Table 8 FCDT vs FCLT
Authors Time point Treatment Mean baseline 
IOPa
Mean treatment 
IOPa
Treatment 
differencea
p-value
Konstas et al (2004) Mos 2 FCDT 20.2(1.9) 17.0(2.0)
FCLT 20.1(2.0) 17.3(2.2) 0.27 0.36
Shin et al Mos 3 FCDT 27.5(3.1) 19.1(3.3)
FCLT 27.9(3.6) 18.5(2.9) 1.0 0.005
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; FCLT, ﬁ  xed combination latanoprost–timolol; IOP, intraocular pressure; mos, months.
Table 9 FCDT vs brimonidine + latanoprost (B + L)
Authors Time point Treatment Peak IOP 
reductiona
% Change p-value
Zabriskie and Netland Mos 3(Study 1) FCDT 6.5 25.3
B + L 9.0 33.9 0.044
Mos 3(Study 2) FCDT 6.6 26.3
B + L 9.1 33.4 0.047
ameasured in mmHg.
SD values provided in parentheses.
Abbreviations: FCDT, ﬁ  xed combination dorzolamide–timolol; IOP, intraocular pressure; mos, months.Clinical Ophthalmology 2008:2(2) 398
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to adverse reactions. Reported in up to 30% of the patients, 
the most common adverse events were taste perversion 
or ocular burning and/or stinging. This was followed by 
report of conjunctival hyperemia, blurred vision, superﬁ  cial 
punctate keratitis or eye itching by 5%–15% of the patients. 
Dorzolamide is the likely culprit since studies have reported 
ocular discomfort associated with dorzolamide (Barnebey 
and Kwok 2000; Silver 2000).
Ophthalmic medications also can pose additional prob-
lems in terms of the accuracy of drops getting into the eye, 
washout of drops and lacrimal drainage. The cul-de-sac of 
the human eye normally contains 7 to 9 μL of tears and has 
a maximum capacity of about 30 μL (Mishima 1981). The 
drop size of commercial glaucoma medications ranges from 
25.1 to 56.4 μL with an average of 39 μL (Lederer and Harold 
1986). Therefore, up to one-half of the medication may spill 
out from the lids at the time of instillation. Especially when 
two solutions are administered simultaneously or too closely 
to each other consecutively, the excess solution drains out of 
the lacrimal system or runs down the cheek. This medication 
washout is decreased by combination formulations, such as 
FCDT, which allows the patient to instill only one drop for 
both medications. Combination therapy also cuts in half the 
toxicity from vehicle in medication delivery and preservatives 
such as benzalkonium chloride (Novack and Evans 2001).
Conclusions
Efﬁ  cacy and safety studies published to date show that the 
ﬁ  xed combination dorzolamide – timolol is more efﬁ  cacious 
than its components used individually, and at least as effective 
as its components used concomitantly in controlled condi-
tions. In uncontrolled clinical settings, the combination for-
mulation may have an additional IOP-lowering beneﬁ  t, most 
likely due to compliance or decreased washout effect. Most 
studies also show ﬁ  xed combination dorzolamide – timolol 
has efﬁ  cacy comparable to other topical agents and combina-
tion agents in lowering the IOP. The role compliance plays 
in medication efﬁ  cacy cannot be understated. As a result of 
increased compliance from ease of use, combination medi-
cation may provide additional beneﬁ  t to the patients. Fixed 
combination dorzolamide – timolol is also generally well
tolerated. This suggests that ﬁ  xed combination dorzolamide – 
timolol may have a beneﬁ  cial role as a replacement or adjunct 
therapy in a clinical glaucoma practice setting when the IOP 
is not adequately controlled with either agent. However, one 
needs to keep in mind study conclusions are based on overall 
population results. Patients respond to the same treatment 
regimen in different ways. Therefore, treatment plans should 
always be individualized and tailored to the patient’s needs 
as they change over time.
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